Alluvi Retatrutide 40mg Injection Pen UK

Buy alluvi retatrutide 40mg uk

Alluvi Retatrutide 40mg is a pharmaceutical-grade triple agonist injection pen available to buy online in the UK from UK Peptides Store. Independently third-party tested to ≥98% purity with Certificate of Analysis on every batch, Alluvi is one of the most trusted retatrutide brands in the UK — known for product consistency, excellent buyer reviews and precise pen dosing.

What is Alluvi Retatrutide?

Retatrutide is a next-generation triple GLP-1/GIP/GCG receptor agonist developed by Eli Lilly. Phase 2 clinical trials published in the New England Journal of Medicine (2023) showed retatrutide produced up to 24.2% body weight reduction at 48 weeks — the highest weight loss result of any GLP-1 class peptide in clinical trials, surpassing both semaglutide and tirzepatide.

Alluvi produces both 20mg and 40mg retatrutide pens. The 40mg pen provides sufficient volume to cover buyers titrating from 8mg upward through to the 12–24mg maintenance dose range.

🔬 View Independent Janoshik COA Verification — Batch #81821 →

alluvi retatrutide 40mg uk — Product Details

• Brand: Alluvi
• Dose per pen: 40mg retatrutide
• Mechanism: Triple GLP-1/GIP/GCG receptor agonist
• Purity: ≥98% — Janoshik independently verified
• COA: Certificate of Analysis on every batch
• Physician review: Included with every order
• Dosing protocol: Personalised titration schedule included
• Storage: Refrigerate 2–8°C. Do not freeze.
• Dispatch: Within 48 hours — Manchester UK

Alluvi vs Synedica Retatrutide — Which Should I Buy?

Both Alluvi and Synedica retatrutide are independently COA verified to ≥98% purity. The key difference is that Alluvi offers both 20mg and 40mg options, making it the preferred choice for buyers who want flexibility across their titration. Synedica is available in 40mg only. If you are starting retatrutide for the first time and prefer to begin at lower doses, consider the Alluvi 20mg pen.

Retatrutide 40mg Dosing — Titration Schedule

Your physician-reviewed protocol is included with every order. Standard titration based on NEJM Phase 2 trial data:

• Weeks 1–4: 2mg once weekly
• Weeks 5–8: 4mg once weekly
• Weeks 9–12: 8mg once weekly — 40mg pen begins to show value here
• Weeks 13–24: 12mg once weekly
• Week 24+: Up to 24mg once weekly (if tolerated)

Phase 2 Clinical Trial Results — What to Expect

In the NEJM Phase 2 trial at the 24mg dose over 48 weeks:

• Average body weight reduction: 24.2%
• Participants losing ≥20% body weight: 83%
• Participants losing ≥25% body weight: 57%

Results at lower maintenance doses (8mg–12mg) averaged 17–22% weight loss. Individual results vary based on diet, activity and protocol adherence. Source: PubMed — Retatrutide Phase 2 Trial (2023)

Not sure which retatrutide is right for you? WhatsApp our team for a free protocol recommendation.

⚠️ For research and physician-supervised use only. Not MHRA approved for clinical use. Not intended to diagnose, treat, cure or prevent any disease. For UK residents 18+ only.